Bone Innovation Summit 13th and 14th February 2019, Lübeck
The Bone Innovation Summit is jointly organised by three projects dealing with bone healing and fractures: The EU Interreg Baltic Sea Region project Baltic Fracture Competence Centre (BFCC), the EU Interreg Deutschland-Danmark project BONEBANK and Northopedics, the innovation-oriented network in Schleswig-Holstein. All projects achieved substantial results and will provide a clear roadmap how e.g. a transnational fracture registry and mesenchymal stem cells could be part of future solutions to foster innovations for better bone healing. The BONEBANK project is co-funded by Interreg Deutschland-Danmark with means from the European Regional Development Fund.
The demographic change, environmental factors and other aspects lead to a strong need for innovative products and improvement in clinical procedures for bone healing and fracture treatment. In this context, it is particularly important that hospitals, industry and researchers work tightly together.
The Bone Innovation Summit will host high-profile plenary speakers, world class researchers and industry representatives to discuss innovative solutions to overcome current challenges and knowledge gaps. It offers the great opportunity to share research findings, promote knowledge exchange and develop innovative ideas during panel discussions and networking.
The city of Lübeck as renowned industry, clinical and research location provides the ideal place for the Bone Innovation Summit on 13th and 14th February 2019.
Get in touch with our international experts and register now!
Over the last decade Professor Hutmacher has gained a worldwide reputation in the field of tissue engineering & regenerative medicine (TE&RM), and his track record illustrates successful mastery of a major challenge in biomedical sciences: the ability to transcend traditional disciplinary boundaries, and initiate and nurture research and educational programs across different disciplines. He is one of the few academics who has taken a holistic bone engineering concept to clinical application. More than 10.000 patients have been treated with the FDA-approved and CE-marked scaffolds developed in collaboration with Osteopore International in Singapore.
The choice for the best therapy of bone fractures with regards to functional outcome and the patient’s life situation needs to consider many factors, i.e. fracture localization, type and morphology. Patient-specific factors such as the degree of osteoporosis and bone infections are posing a particular challenge for the clinician. In the session DIAGNOSTICS & TREATMENTS international experts from research, clinic and industry will present latest trends of diagnosing and treating of fractures with a risk of osteoporosis and infection.
An ageing society increases the need for innovative products and clinical procedures to respond to age-related fractures and co-morbidities and cause such as osteoporosis, infections and non-unions. Innovations in fracture management need to reduce the cost of care, improve the quality of care and functional outcome. At which point innovations have to start in the future and what these innovations can look like, international experts from research, hospitals and industry will show in the session FRACTURES & INNOVATION. Furthermore, partners will present the corresponding results and findings of the BFCC project.
Healthcare-acquired infections remain one of the most critical complications following orthopedic and trauma surgery. When planktonic bacteria are present, they can be effectively handled by the immune system and an appropriate antibiotics therapy. Implant surfaces however, provide an environment where bacteria are able to populate and build stable biofilms which are more difficult to defend. Evolving pathogens such as antibiotic resistant strains dramatically worsen the situation for patients, care givers and the healthcare system. The session INFECTIONS and IMPLANTS will address and discuss this issue from a clinical and academic perspective. Latest advancements in biofilm diagnostics (Svetlana Karbysheva) and laboratory testing (Katharina Maniura) will be presented and local differences in clinical infection rates in the Baltic Sea Region will be highlighted (Šarūnas Tarasevičius). Finally, strategies to prevent biofilm formation on implants will be discussed by international experts (Rainer Burgkart, Wolfgang Streit).
Life Science Nord is committed to innovative medicine in Hamburg and Schleswig-Holstein, Germany. Within the regional cluster for medical technology and biotechnology/pharma there are 49,900 employees working for about 500 innovation-oriented companies. In 2016, the industry generated a gross value of 4,3 bn Euro and the cluster's exports were 4,2 bn Euro. Additionally, the region hosts internationally renowned research institutes, universities and university clinics. Together they represent the entire value chain necessary for the emergence of new treatments and medical devices: from research, development and clinical studies, to manufacturing, marketing and sales. Life Science Nord strengthens this regional industry and is a visible entity on the European stage.
With locations in Kiel and Lübeck, University Medical Center Schleswig-Holstein (UKSH) is one of Europe’s largest medical centres and covers the entire spectrum of modern medicine and health care. The only maximum care provider in Schleswig-Holstein comprises more than 80 clinics and institutions with 2,000 physicians, scientists, researchers, and health staff of 4,000 people.
BFCC is a pan-Baltic fracture cooperation network fostering innovation within fracture management. The project consortium consists of a transnational cross-sector partnership involving five hospitals, three companies from the medical technology industry, a research institution, three clusters and one technology transfer organisation.
BONEBANK: The German-Danish Biobank and Innovation Platform for Stem Cells in Bone Regeneration
Currently, bone and bone fragments with valuable stem cells are disposed as waste material during fracture-related routine operations. However, these stem cells have a high potential for regenerative therapies as for instance in the treatment of bone fractures. BONEBANK aims at harvesting these stem cells with new instruments and methods and to store them in a cross-border biobank. Therefore, this useful resource can be used for therapeutic purposes or for the development of new therapies.
Northopedics: The north´s innovation network for bone healing
It is forecasted that about 34% of the German population will be 65 or older in 2060. This suggests an increase of frequency of musculoskeletal diseases, including osteoporosis and arthritis, which are more prevalent in elderly people. Consequently, costs of treatment and the need to remain activity and mobility in old age will probably rise. These trends show the need to develop innovative bone healing solutions. There are excellent skills in hospitals, the scientific community and industry in the Northern Germany, which is mostly reflected by members of the Life Science Nord cluster. The NORTHOPEDICS project, launched in 2016, established an innovation network for bone healing in which regional expertise is pooled and interdisciplinary and intersectoral cooperation is promoted. The aim is to step up research and development efforts to develop and produce new ideas, approaches, products, methods and services in the field of bone healing.
At its German location in Schönkirchen near Kiel, the Stryker Trauma GmbH is specialised in the development and production of intramedullary nails. As such, the Stryker Trauma GmbH is the world leader in intramedullary nailing with an annual production of 400,000 nails. Statistically, every 90 seconds a nail from Schönkirchen is implanted worldwide.
soventec is a software engineering company with ISO 13485 QM certification and 19 years experiences in the field of research and medical devices automation. soventec’s software product Lab OS® manages samples in biobanks and repositories with high quality documentation and the possibility to automate laboratory devices. soventec is also providing software development services in the field of laboratory data management, laboratory device integration, automation and scheduling for companies and institutions in life sciences, biotechnology, pharma, medical devices and medicine.
BONESUPPORT is an innovative commercial stage orthobiologics company, based in Lund, Sweden. The company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that are based on the novel and proprietary CERAMENT® technology platform. The commercial products, CERAMENT®|BONE VOID FILLER, CERAMENT®|G (gentamicin) and CERAMENT®|V (vancomycin) deliver important clinical benefits to patients and surgeons due to their ability to remodel to the patient’s own bone and to elute antibiotics directly into the bone void to protect the healing process. These products target a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot. In the BFCC project (Pilot-Infection), the Lithuanian University has investigated the elution of vancomycin from CERAMENT® V in a clinical study on 9 trochanteric hip fractures. The results have increased the knowledge in the in-vivo long-term elution of vancomycin.
Bone Index is one of the most promising Life Science Company in Scandinavia 2014 (Nordic Star Award) and one of Europe's top new manufacturers of medical devices 2015 (Healthtech Summit). Earlier this year (2018), the American Medical Association issued a new reimbursement code for Bindex® and the Centers for Medicare & Medicaid Services (CMS) has approved coverage for the code in several settings. The mission is to reduce the number of osteoporotic fractures by one million globally per year and thus increase the quality of life of families. The aim is bring the diagnostics from special healthcare to primary healthcare with Bindex® point-of-care technology.
According to the basic European general data protection regulation, GDPR, ScanBalt fmba is obliged to inform members, newsletter subscribers and visitors to our webs that we handle personal data. The personal data can be name, postal address, e-mail address and phone number. The information is used e.g. to forward invoices for member fees or to forward newsletters and invitations. If you do not wish any longer to subscribe to our newsletters press the “Unsubscribe” link below. When you visit our websites, the servers automatically store the information that the browser sends when you visit the websites.